From: Inhaled β-agonist does not modify sympathetic activity in patients with COPD
Gender | Male, n (%) | 21 (65.6) |
Female, n (%) | 11 (34.4) | |
Age [years] | 61.2 ± 8.4 | |
Body weight [kg] | 81.5 ± 19.8 | |
Height [cm] | 174.6 ± 7.6 | |
Body mass index [kg/m2] | 26.5 ± 5.2 | |
First diagnosis of COPD [months before screening) | 59.0 ± 62.3 | |
GOLD stage | II (moderate COPD), n (%) | 14 (45.2) |
III (severe COPD), n (%) | 17 (54.8) | |
COPD symptoms | Breathlessness, n (%) | 31 (96.9) |
Cough, n (%) | 24 (75.0) | |
Sputum production, n (%) | 21 (65.6) | |
FEV 1 [L] | 1.6 ± 0.4 | |
FEV 1 [% predicted] | 50.2 ± 9.9 | |
FVC [L] | 2.9 ± 0.8 | |
FEV 1 /FVC [%] | 54.5 ± 9.2 | |
Smoking status | Previous smoker, n (%) | 13 (40.6) |
Smoker, n (%) | 19 (59.4) | |
Cessation of smoking [months before screening] | 54.0 ± 47.4 | |
Pack years | 43.1 ± 17.7 |